What is the best empiric antibiotic treatment regimen in adults hospitalized with community‐acquired pneumonia?. Issue 12 (December 2017)

• Record Type: Journal Article
• Authors: Gaba, Payal; Johansing, Patrick
• Is Part Of: Evidence-based practice. Volume 20:Issue 12(2017)
• Publication Date: 2017-12
• DOI: 10.1097/01.EBP.0000541903.27973.1d
• Languages: English
• ISSNs: 1095-4120

Abstract

Abstract : EVIDENCE‐BASED ANSWER : Fluoroquinolone monotherapy or a beta‐lactam combined with a macrolide are both associated with lower 30‐day mortality rates than beta‐lactam monotherapy in adults hospitalized with communityacquired pneumonia (CAP) (SOR: B, systematic review of observational studies and RCTs). Macrolide use is associated with reduced mortality compared with nonmacrolide therapies in critically ill adults (SOR: B, systematic review of observational studies). Either a respiratory fluoroquinolone or a beta‐lactam plus macrolide should be used for hospitalized patients outside of the intensive care unit (ICU), and a betalactam plus either a fluoroquinolone or azithromycin should be used for patients in an ICU (SOR: C, expert opinion).